As of Feb 03, 2025, Abbott Laboratories's Discounted Cash Flow (DCF) valuation estimates its share price at $103.5. This suggests it may be overvalued by (19.4%) compared to its current price of around $128.5, using a WACC of 7.4% and growth rates of 3.0%.
As of Feb 03, 2025, Abbott Laboratories's Weighted Average Cost of Capital (WACC) is approximately 7.4%.
As of Feb 03, 2025, Abbott Laboratories's Enterprise Value (EV) is approximately $188.2B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.